BLADDER UROTHELIAL CARCINOMA

This early-phase study tests two or three drugs together (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced cancers of the urinary and genital systems that have spread. The main goals are to find the safest dose and understand side effects. About 152 adul…

This study tests a combination of radiation therapy and two immunotherapy drugs (durvalumab with or without tremelimumab) in people with advanced bladder cancer that cannot be surgically removed or has spread. Participants either cannot have chemotherapy or have chosen not to. Th…

This early-phase study tests whether adding the blood-pressure drug propranolol to standard immunotherapy and chemotherapy can improve outcomes for people with bladder cancer that has spread to nearby lymph nodes. About 12 participants will receive the combination before surgery …

This study was designed for people with muscle-invasive bladder cancer who cannot receive the standard chemotherapy drug cisplatin. It aimed to test whether the targeted therapy erdafitinib, alone or combined with the immunotherapy atezolizumab, could shrink tumors before surgery…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. About 95 adults will receive either chemoradiation alone or chemoradiation…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with muscle-invasive bladder cancer live longer without their cancer returning. About 475 adults with localized disease that hasn't spread are taking part. The goal is to s…